We scan new podcasts and send you the top 5 insights daily.
Dr Sands notes small cell lung cancer scans often show waxing and waning inflammatory findings. That makes a grade 1 radiographic ILD hard to attribute to a B7H3 antibody-drug conjugate; if drug-related ILD is suspected, he says hold the drug, treat aggressively with steroids, and monitor for improvement.
The discovery of low-grade, asymptomatic interstitial lung disease (ILD) on scans for patients on certain ADCs does not mandate permanent discontinuation. By holding the drug, initiating steroids, and involving pulmonology, the inflammation can resolve, often allowing the patient to safely resume a highly effective therapy.
With ADCs carrying a risk of interstitial lung disease (ILD), a critical safety measure is to act on radiological findings alone. Even if a patient is completely asymptomatic, new ground-glass opacities on a CT scan require an immediate treatment hold to prevent potentially rapid and severe pneumonitis.
To manage the risk of interstitial lung disease (ILD) with TDXD, experts now recommend routine screening with high-resolution chest CT scans every 6-12 weeks. This practice aims to catch asymptomatic, grade 1 ILD early, allowing for treatment holds and steroid intervention, which may preserve the option to rechallenge.
For patients with lung metastases and symptoms like shortness of breath, choosing an ADC becomes complex. The primary concern is the inability to distinguish between disease progression and drug-induced interstitial lung disease (ILD), a known risk with certain ADCs. This diagnostic ambiguity can lead clinicians to favor ADCs with a lower ILD risk profile.
Unlike pneumonitis from immune checkpoint inhibitors, which responds quickly to steroids, pneumonitis from ADCs like trastuzumab deruxtecan is less responsive and slower to resolve. This critical difference requires a lower threshold for holding therapy and more cautious management to avoid permanent lung damage.
The management of treatment-induced pneumonitis differs significantly between drug classes. While clinicians may treat through low-grade pneumonitis from immune checkpoint inhibitors, the safest approach for antibody-drug conjugates (ADCs) like TDXD is to stop the drug immediately upon any radiographic evidence, even if the patient is asymptomatic.
While oncologists feel comfortable re-challenging patients after grade 1 asymptomatic radiographic pneumonitis resolves—monitoring them closely with six-week CT scans—they refuse to restart trastuzumab deruxtecan following grade 2 ILD. Current clinical literature lacks sufficient safety evidence to justify retreating grade 2 toxicity, leading clinicians to draw a strict line against restarting therapy.
Unlike some immunotherapy guidelines, experts recommend immediate steroid treatment for even Grade 1 (asymptomatic) ADC-induced pneumonitis or interstitial lung disease (ILD) found on scans. This aggressive, proactive approach is considered necessary due to the risk of rapid clinical deterioration, prioritizing safety and the ability to resume cancer therapy.
Clinicians are abandoning watchful waiting in favor of proactive mitigation to avoid fatal pulmonary complications from mirvetuximab. Even asymptomatic patients showing rapid radiographic ground-glass changes can safely receive short, quick steroid tapers rather than the prolonged multi-month regimens used for checkpoint inhibitors.
To proactively screen for interstitial lung disease (ILD), a serious risk with trastuzumab deruxtecan (TDXD), imaging should be conducted more frequently than the typical 12-week interval. The recommended strategy is to scan patients every nine weeks, or after every three cycles, to identify asymptomatic Grade 1 ILD cases early.